Health
FDA Approves First Drug to Treat Rare Metabolic Disorder – PharmiWeb.com
SILVER SPRING, Md., Nov. 23, 2020 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria…
SILVER SPRING, Md., Nov. 23, 2020 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of experts and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.
“The approval of Oxlumo represents a great triumph of community involvement to address a rare disease. It is a result of…
